| Market Cap | $244.23M-67.5% |
| Revenue (ttm) | n/a |
| Net Income | -$105.28M |
| EPS | -$1.13 |
| Shares Out | 82.79M |
| PE Ratio | n/a |
| Forward PE | -1.99 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,164,487 |
| Open | $2.93 |
| Previous Close | $2.95 |
| Day's Range | $2.87 - $3.21 |
| 52-Week Range | $2.55 - $10.99 |
| Beta | 1.65 |
| Analysts | Strong Buy |
| Price Target | $25.11(+751.22%) |
| Earnings Date | Nov 16, 2026 |
About LXEO
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company is also developing LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy. In addition, it is developing LX1001, LX1020, and LX1021, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease. The company has a license agreement with Cornell University to conduct the Phase 1/2 clinical trial of LX1001, as well as support the development of the LX1004 program; a research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate. The company was founded in 2017 and is headquartered in New York, New York.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
2 firms rating LXEO in the last 3 months, one vote each. Issuer-paid research is not counted.
$LXEO stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in LXEO holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by LXEO's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
LXEO Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New LXEO patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to LXEO from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from LXEO’s recent data — informational, not investment advice
What’s Behind the Score
News check: Strong positive clinical trial data with 80% reduction in cardiac episodes, analyst upgrade, and regulatory progress indicate bullish outlook for LX2020.
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| BBC | Virtus Biotech Clinical Trials ETF | 0.52% |
| BUSM | EA Series Trust - EA Bridgeway Ultra-Small Company Market ETF | 0.16% |
| KOMP | State Street SPDR S&P Kensho New Economies Composite ETF | 0.07% |
| IWC | iShares Micro-Cap ETF | 0.05% |
| XBI | State Street SPDR S&P Biotech ETF | 0.05% |
| FSEV | Fidelity Enhanced Small Cap Value ETF | 0.03% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 0.02% |
| IBB | iShares Biotechnology ETF | 0.01% |
| BIB | ProShares Ultra Nasdaq Biotechnology | 0.01% |
| PWS | Pacer WealthShield ETF | 0.01% |
| LABU | Direxion Daily S&P Biotech Bull 3X Shares | 0.01% |
Weight is the stock’s share of each fund’s holdings.
